ArticleNature aging2026
Reframing the epidemiological transition as increasing returns to tackling aging-related diseases.
Article in Nature aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aging rises, yet the double burden of illness remains.Nature aging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Global life expectancy has risen since 1973 from 58 to over 73 years, while the share of people aged 65 years and older has doubled to 10% and is projected to reach 21% by 2073. This shift is linked to an epidemiological transition from infectious to chronic disease. Here, using Global Burden of Disease data, we reframe this transition by statistically grouping diseases on the basis of their impact over the life cycle, yielding four clusters: infant, early-adult, later-adult and aging-related. We show aging-related diseases are the largest part of the current global disease burden and the greatest lifetime burden for a newborn, even in low-income countries. Aging-related diseases possess two distinctive properties: a tight link between mortality and morbidity, and increasing returns, whereby reductions in their prevalence makes further gains even more attractive. The implications of this recasting of the epidemiological transition for health systems and aging research are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.